The recent Medical-Tech-SaaS IPO had some problems in their S-1 report. I expect it to sink to "below ipo level" as the problems could show up in 1-2 quaters after IPO.
The problem is called "Medicity buyout" and hiding the price of acquision besides the main datasheet in S-1.
Second problem is that it has very slow growth.
The problem is called "Medicity buyout" and hiding the price of acquision besides the main datasheet in S-1.
Second problem is that it has very slow growth.
코멘트:
-10%
거래청산: 타겟 닿음:
now 32